CA50633/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
1990	1
1992	2
1993	4
1994	1
1995	2
1996	1
1997	1
1998	1
1999	1
2000	1
2001	1
2004	1
2006	1
2007	1
2010	3
2011	2
2012	3
2013	1
2014	1
2015	4
2017	1
2018	1
2024	0

1

Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.

AlDeghaither D, Smaglo BG, Weiner LM. AlDeghaither D, et al. J Clin Pharmacol. 2015 Mar;55 Suppl 3(0 3):S4-20. doi: 10.1002/jcph.407. J Clin Pharmacol. 2015. PMID: 25707963 Free PMC article. Review.

2

Mechanisms of action of therapeutic antibodies for cancer.

Redman JM, Hill EM, AlDeghaither D, Weiner LM. Redman JM, et al. Mol Immunol. 2015 Oct;67(2 Pt A):28-45. doi: 10.1016/j.molimm.2015.04.002. Epub 2015 Apr 23. Mol Immunol. 2015. PMID: 25911943 Free PMC article. Review.

3

New approaches to antibody therapy.

Weiner LM, Adams GP. Weiner LM, et al. Oncogene. 2000 Dec 11;19(53):6144-51. doi: 10.1038/sj.onc.1204000. Oncogene. 2000. PMID: 11156528 Review.

4

Antibody-based immunotherapy of cancer.

Weiner LM, Murray JC, Shuptrine CW. Weiner LM, et al. Cell. 2012 Mar 16;148(6):1081-4. doi: 10.1016/j.cell.2012.02.034. Cell. 2012. PMID: 22424219 Free PMC article. Review.

5

Fully human therapeutic monoclonal antibodies.

Weiner LM. Weiner LM. J Immunother. 2006 Jan-Feb;29(1):1-9. doi: 10.1097/01.cji.0000192105.24583.83. J Immunother. 2006. PMID: 16365595 Review.

6

Cancer immunology for the clinician.

Weiner LM. Weiner LM. Clin Adv Hematol Oncol. 2015 May;13(5):299-306. Clin Adv Hematol Oncol. 2015. PMID: 26352774 Review.

7

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

Weiner LM, Surana R, Wang S. Weiner LM, et al. Nat Rev Immunol. 2010 May;10(5):317-27. doi: 10.1038/nri2744. Nat Rev Immunol. 2010. PMID: 20414205 Free PMC article. Review.

8

Vaccine prevention of cancer: can endogenous antigens be targeted?

Weiner LM, Surana R, Murray J. Weiner LM, et al. Cancer Prev Res (Phila). 2010 Apr;3(4):410-5. doi: 10.1158/1940-6207.CAPR-10-0040. Epub 2010 Mar 23. Cancer Prev Res (Phila). 2010. PMID: 20332297 Free PMC article. Review.

9

Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.

Smith JP, Wang S, Nadella S, Jablonski SA, Weiner LM. Smith JP, et al. Cancer Immunol Immunother. 2018 Feb;67(2):195-207. doi: 10.1007/s00262-017-2077-9. Epub 2017 Oct 17. Cancer Immunol Immunother. 2018. PMID: 29043413 Free PMC article.

10

Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death.

Ratushny V, Pathak HB, Beeharry N, Tikhmyanova N, Xiao F, Li T, Litwin S, Connolly DC, Yen TJ, Weiner LM, Godwin AK, Golemis EA. Ratushny V, et al. Oncogene. 2012 Mar 8;31(10):1217-27. doi: 10.1038/onc.2011.314. Epub 2011 Jul 25. Oncogene. 2012. PMID: 21785464 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

31 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year